Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer - Concepedia

Concepedia

Publication | Open Access

Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer

DOI Full Paper Access

546

Citations

39

References

2005

Year

Stephen E. Jones, John K. Erban, Beth Overmoyer, G. T. Budd, Laura F. Hutchins, EE Lower, Leslie Rodgers Laufman, S. Sundaram, W J Urba, Kathleen I. Pritchard,

Journal of Clinical Oncology

Abstract

Docetaxel was superior to paclitaxel in terms of OS and TTP. ORR was higher for docetaxel. Hematologic and nonhematologic toxicities occurred more frequently in the docetaxel group. The global quality-of-life scores were similar for both agents over time.

References

	Year	Citations

Page 1